通过免疫组化技术检测肿瘤细胞联合免疫细胞中PD-L1综合阳性评分(combined positive score,CPS)预测PD-1/PD-L1抑制剂疗效成为临床关注的热点问题[8-9]。本研究针对北京大学第一医院2016-2019年接受新辅助治疗的早期TNBC病例进行回顾性分析,探索...
(NCT02819518), which investigated the clinical validity of PD-L1 IHC 22C3 pharmDx in identifying patients with PD-L1 expressing Combined Positive Score (CPS) ≥ 10 in previously untreated locally recurrent unresectable or metastatic TNBC.1 The role of immune checkpoint inhibitors for breast cancer ...
Overall, the 5-year breast cancer cause-specific survival was 81.5% [95% confidence interval (CI) 77.6-85.5]. The 5-year, cause-specific survival by CPS+EG score was 93.8% score 0, 89.9% score 1, 90.7% score 2, 84.8% score 3, 67.7% score 4, and 43.4% score 5/6. CPS+EG ...
therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) a...
Either MRTF-A pathway blockers or histone methylation inhibitors might be considered as novel candidates for the therapy of breast cancer metastasis. Keywords: 17β-estradiol; migration; breast cancer cells; MRTF-A; SMYD3 Acknowledgements: This work was financially supported by the National Natural ...
score, scream**, screen, sculpture**, sea, search, season, seat, second, secondary**, secret, secretary, section*, secure**, security**, see, seed**, seek*, seem, seize**, seldom, select*, sell, send, senior*, sense, sensitive**, sentence, separate, September, series*, serious,...
CPS-EG scoreTriple-negative breast cancerNeoadjuvant chemotherapyBiomarkerPathological complete responseKi-67 indexThis study aimed to establish risk groups on the basis of CPS-EG scores, independent of pCR status, in triple-negative breast cancer (TNBC) patients receiving neoadjuvant chemotherapy (NACT)...
通过免疫组化技术检测肿瘤细胞联合免疫细胞中PD-L1综合阳性评分(combined positive score,CPS)预测PD-1/PD-L1抑制剂疗效成为临床关注的热点问题[8-9]。本研究针对北京大学第一医院2016-2019年接受新辅助治疗的早期TNBC病例进行回顾性分析,探...
Background and aims Evaluation of the programmed cell death ligand-1 (PD-L1) combined positive score (CPS) is vital to predict the efficacy of the immunotherapy in triple-negative breast cancer (TNBC), but pathologists show substantial variability in the consistency and accuracy of the ...
This association is strongest in triple-negative breast cancer (TNBC). The CPS+EG system, based on pre-treatment clinical (CS) and post-treatment pathologic stage (PS), grade and estrogen receptor status, leads to a refined estimate of prognosis after NACT in all comers and HR+/HER2- (...